Results 231 to 240 of about 208,301 (303)

Integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34‐mutant reveals universal TP53 abnormalities

Brain Pathology, EarlyView.
This integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34‐mutant expands the spectrum of associated genetic changes and underscores the presence of universal TP53 abnormalities at copy number, sequence, and protein expression level, with frequent yet largely unrecognized TP53 copy‐neutral loss of ...
Jorge A. Trejo‐Lopez, Cinthya Zepeda Mendoza, Thomas M. Kollmeyer, Kristen L. Drucker, Vanessa M. Pazdernik, Paul A. Decker, Corinne E. Praska, Jayson Hardcastle, Stephanie Smoley, Matthew Isaacson, Mallika Gandham, Surendra Dasari, Aditya Raghunathan, Caterina Giannini, Gang Zheng, Aaron Wagner, M. Beatriz Lopes, Kar‐Ming A. Fung, JoElle G. Peterson, Andreana L. Rivera, Christopher Rossi, Meggen A. Walsh, Zied Abdullaev, Kenneth Aldape, Martha Quezado, Drew Pratt, Patrick Joseph Cimino, Robert B. Jenkins, Cristiane M. Ida   +28 more
wiley   +1 more source

Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort. [PDF]

Cancer Med
Zhao Y, Zhao T, Tang F, Mo X, Chang Y, Zhao X, Xu L, Wang Y, Zhang X, Jiang H, Jiang Q, Huang X, Sun Y.   +12 more
europepmc   +1 more source

Clinical and molecular features of primary gliosarcoma with digital spatial whole‐transcriptome analysis of glial and mesenchymal components

Brain Pathology, EarlyView.
We report the clinical and genetic features of an institutional cohort of primary adult gliosarcomas compared to glioblastoma. We performed spatial whole‐transcriptome analysis on glial and sarcomatous regions of four cases to compare gene expression profiles and validated differential protein expression for two markers in tissue sections.
Matthew D. Wood, Gabriel Zangirolani, Jinho Lee, Melanie H. Hakar, Tanaya Neff, Kevin Y. Zhang, Christopher L. Corless   +6 more
wiley   +1 more source

Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapies

Vicent S, Welch C, Novoa-Jaso G, Vasquez-Valencia C, Macaya I, Jimenez-Alonso JJ, Subrizio A, Fernández-Lagos A, Llorente S, Jimenez M, Prados-Carvajal R, Moreno H, Lopez I, Bakartxo N, Rub J, Ratia ACD, Battuello P, Bujanda-Cundin X, Huertas P, Macaruya T, Paz-Ares L, Crisafulli G, Calvo A, Guruceaga E, Tammela T, Martinez-Monge R, Lecanda F, Bardelli A, Ferrer I, Tian T, Russo M.   +30 more
europepmc   +1 more source

Ovarian Cancer Susceptibility and Chemosensitivity to KRAS Modulation. [PDF]

Int J Mol Sci
Psaras AM, McKay SJ, Vasquez Vilela J, Ospina Sanchez E, Cintrón MG, Elder KK, Brooks TA.   +6 more
europepmc   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors. [PDF]

J Enzyme Inhib Med Chem
Baig MH, Jo YS, Nale SD, Kim CJ, Park J, Ha J, Moon B, Ryu S, Dong JJ.   +8 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Mutant KRAS in brain endothelial cells promotes vascular inflammation and impairs vascular integrity in brain arteriovenous malformation. [PDF]

J Cereb Blood Flow Metab
Park JE, Freeman BH, Park H, Kim S, Bafor AE, Myint O, Gao S, Xu Z, Körbelin J, Aronowski J, Chen PR, Kim E, Park ES.   +12 more
europepmc   +1 more source